Ben's parents Allyn and Jenny have said they would not have cremated their son if they knew there were questions over his ...

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to ...

TORONTO - Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has announced the completion of a private placement funding round on February 12, 2025, raising approximately ...

JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, has initiated a public offering of its ordinary shares along with pre-funded ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Babies born during the COVID-19 pandemic had much lower risk for respiratory infections and antibiotic prescriptions during their first 18 months.

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for th ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

The challenges of translating neuroprotective interventions with promising efficacy in animal studies into effective treatments for patients with stroke are well documented, with issues including ...

Respiratory ... They range from acute infections, such as pneumonia and bronchitis, to chronic conditions such as asthma and chronic obstructive pulmonary disease. In this phase 1/2 trial ...